Related Experiment Video

Updated: Oct 12, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

[Results and problems in the treatment of childhood leukaemia (author's transl)]

D Schuler, T Révész, A Horváth

    Monatsschrift Fur Kinderheilkunde
    |January 1, 1978
    PubMed

    Insights

    Childhood leukemia treatment improved survival rates, with over 50% of acute lymphoblastic leukemia (ALL) patients alive at 3 years. Bimonthly Vincristine-Prednisolone maintenance therapy proved more effective than monthly treatments.

    Area of Science:

    • Pediatric Oncology
    • Hematology
    • Clinical Trials

    Background:

    • The Hungarian Study Group for Childhood Leukaemia was established in 1971 to standardize treatment protocols.
    • Complex chemotherapy regimens were implemented for childhood leukemia patients.

    Purpose of the Study:

    • To evaluate the survival rates of children with leukemia undergoing uniform treatment schedules.
    • To compare the efficacy of two different maintenance therapy protocols for acute lymphoblastic leukemia (ALL).

    Main Methods:

    • A cohort of 391 children with leukemia received chemotherapy based on established treatment schedules.
    • Two maintenance therapy strategies were compared starting in 1974: monthly "pulses" versus every-second-month "pulses" of Vincristine-Prednisolone.

    Main Results:

    • Survival rates showed an increasing trend, with over 50% of ALL patients surviving 3 years post-treatment initiation.
    • One patient achieved a complete remission lasting over 9 years.
    • Bimonthly Vincristine-Prednisolone "pulses" demonstrated superior outcomes compared to monthly "pulses".

    Conclusions:

    • Uniform treatment schedules have improved survival in childhood leukemia.
    • Optimized maintenance therapy, specifically bimonthly Vincristine-Prednisolone, enhances long-term remission rates in ALL patients.

    More Related Videos

    Modeling Chemotherapy Resistant Leukemia In Vitro08:41

    Modeling Chemotherapy Resistant Leukemia In Vitro

    Published on: February 9, 2016

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia08:31

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

    Published on: October 17, 2025

    Related Concept Videos

    Disorders of Leukocytes01:27

    Disorders of Leukocytes

    Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
    Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
    Bone Marrow Sampling and Transplants01:22

    Bone Marrow Sampling and Transplants

    Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
    The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
    Antiprotozoal Agents01:21

    Antiprotozoal Agents

    Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...